Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 99 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: concurrent temozolomide Clear all

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation; Drug · Other · Radiation
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Santa Barbara, California + 7 more

Conditions: Glioblastoma
Interventions: Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies; Biological · Drug
Lead sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: San Diego Pacific Oncology & Hematology Associates; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide; Radiation · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more

Conditions: Glioblastoma
Interventions: Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy; Drug · Other · Radiation
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Brain and Central Nervous System Tumors
Interventions: nelfinavir mesylate, temozolomide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphopenia, Malignant Glioma
Interventions: Laboratory Biomarker Analysis, NT-I7, Placebo; Other · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more

Conditions: Glioblastoma (GBM)
Interventions: Ketogenic Diet, Radiation therapy, Temozolomide; Dietary Supplement · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions: Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide; Drug · Radiation · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions: pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, temsirolimus, temozolomide; Other · Procedure · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 11
States / cities: Jacksonville, Florida • Clive, Iowa • Des Moines, Iowa + 2 more

Conditions: Glioblastoma, Surgery, High Grade Glioma
Interventions: Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide); Radiation · Drug · Procedure
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Danville, Pennsylvania • Wilkes-Barre, Pennsylvania

Conditions: Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Interventions: Chemotherapy with Temodar., Radiation therapy; Drug · Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Glioma, Myelosuppression
Interventions: Medical Chart Review; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glioblastoma (GBM)
Interventions: BGB-58067; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: High-grade Glioma
Interventions: MR-Linac System, Radiation Therapy, Temozolomide; Device · Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions: Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample; Radiation · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: Brain Tumor
Interventions: PPX +TMZ+XRT; Drug
Lead sponsor: howard safran; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Brain and Central Nervous System Tumors
Interventions: concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day, concurrent RAD001 5 mg/day, post-radiation RAD001 10 mg/day, post-radiation temozolomide; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 34
States / cities: Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 28 more

Conditions: Adult Glioblastoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide; Other · Biological · Radiation + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions: erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 139
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more

Conditions: Glioblastoma
Interventions: Lymphocyte harvesting & reinfusion; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma Multiforme, Gliosarcoma
Interventions: ZD6474, temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Patrick Y. Wen, MD; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 7
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Glioblastoma
Interventions: Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab, Temozolomide, Poly-ICLC; Radiation · Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors
Interventions: irinotecan hydrochloride, temozolomide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 118
States / cities: Phoenix, Arizona • Burbank, California • Fresno, California + 91 more

Search by objective public record fields.

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Neoadjuvant Chemoradiation for Resectable Glioblastoma

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac

Embryonal Tumor With Multilayered Rosettes

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme